PlantForm is offering to current shareholders an opportunity to purchase additional shares at $0.75 per share. The minimum subscription is $25,000. The closing date for the transaction is Tuesday, Sept. 20.
Funds raised will be used as general working capital for ongoing research and development on a second product candidate and to complete the animal efficacy studies currently in progress on SEB trastuzumab for breast cancer.
For more information, please contact Don Stewart
, President and CEO, or Ron Hosking
AGM Sept. 20
PlantForm’s annual general meeting takes place Tuesday, Sept. 20 at 10:30 a.m. at 1920 Yonge St., Suite 200, Toronto, M4S 3E2.
Please email your intent to attend (and your proxy form if not attending) to email@example.com
or fax to: (416) 572-7501.
PlantForm will be presenting at the following events:
Keiretsu Life Sciences Forum, New York City, Sept. 20
Landmark Venture Forum, Greenwich, CT, Sept. 22
Abu Dhabi Medical Congress Show, Abu Dhabi, Oct. 23-25
Agriculture 2.0, Toronto, Nov. 7-8
Landmark “Investing for Cures” conference, New York City, Nov. 9.
Sarnia office opens
PlantForm has opened an office in the University of Western Ontario Research and Development Park (Sarnia-Lambton Campus).
1086 Modeland Road
Sarnia, Ontario N7S 6L2
Phone: (519) 333-6736
Fax: (519) 333-6735
Don Stewart, PhD
President & CEO
Ron Hosking, CA
Chief Financial Officer
Chris Hall, PhD
Chief Scientific Officer